Skip to main content
Premium Trial:

Request an Annual Quote

MD Anderson Nets More Than $22M in CPRIT Funding

NEW YORK (GenomeWeb) – The University of Texas MD Anderson Cancer Center said this week that it has been awarded more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT), including several awards for omics-related projects.

Across Texas institutions, CPRIT awarded a total of 73 new grants worth a cumulative $112 million. MD Anderson's CPRIT awards included $14.8 million for research, $6 million in recruitment funding, and $1.4 million for evidence-based cancer prevention services.

Individual projects to be funded at MD Anderson include:

  • $900,000 for an effort to exploit molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanoma

  • $900,000 to develop mechanisms and targeting strategies for SWI/SNF mutations in cancer

  • $900,000 to investigate the genetic and molecular mechanisms underlying the RAS/ERK substrate network

  • $891,938 to examine exosomal DNA as a surrogate biomarker for early diagnosis and therapeutic stratification in pancreatic cancer

  • $897,627 to implement radiogenomic screens to identify novel proliferation-associated glioblastoma genomic therapeutic targets

  • $900,000 to identify new epigenetic vulnerabilities in pancreatic cancer

  • $900,000 to investigate a novel epigenetic reader as a therapeutic target in MLL-translocated pediatric leukemias

  • $1.5 million for the early detection of ovarian cancer with tumor-associated proteins and autoantibodies